Skip to main content

Table 3 Treatment in the C and F group*

From: Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series

Treatment Presence Absence Df P value
cADV#    1 0.017b
 C 81(89.0%) 10(11.0%)
 F 19(67.9%) 9(32.1%)
rADV    1 0.001b
 C 4(4.4%) 87(95.6%)
 F 8(28.6%) 20(71.4%)
ETV    1 0.060a
 C 51(56.0%) 40(44.0%)
 F 10(35.7%) 18(64.3%)
Phos.    1 0.210a
 C 53(58.2%) 38(41.8%)
 F 20(71.4%) 8(28.6%)
Calcium    1 0.001a
 C 47(51.6%) 44(48.4%)
 F 3 (10.7%) 25(89.3%)
Calcitriol    1 0.185a
 C 52(57.1%) 39(42.9%)
 F 12(42.9%) 16(57.1%)
BM    1 0.755b
 C 6(6.6%) 85(93.4%)
 F 3(10.7%) 25(89.3%)
  1. *Ninety-one and 28 patients had treatment in the C and F group, respectively
  2. cADV ceased Adefovir Dipivoxil, rADV reduced Adefovir Dipivoxil, ETV entecavir, Phos. Phosphate supplement, Calcium Calcium supplement, Calcitriol Calcitriol supplement, BM drugs regulating bone metabolism
  3. a Pearson Chi-square test
  4. bCorrected Pearson Chi-square test